Tempus AI, Inc.

Tempus AI, Inc. is a healthcare technology company founded in 2015 that builds data and artificial intelligence systems designed to make clinical and molecular data usable by physicians at the point of care. Its technology is applied chiefly in oncology and precision medicine, where it supports treatment decisions and, increasingly, drug discovery and clinical diagnostics work for life-sciences customers. The company operates in the United States and maintains what it describes as the world's largest library of clinical and molecular data.

The company's platform reach is substantial: it reports connections with roughly 65% of Academic Medical Centers and more than 50% of US oncologists. Products include Tempus One, an AI-enabled assistant; Lens, a data platform; and a set of genomic sequencing assays used to inform treatment decisions. The underlying technical work spans machine learning, genomic sequencing, data science and real-time data platforms.

Engineering and technical hiring sits within interdisciplinary teams in which engineers, data scientists and healthcare experts work alongside biologists and clinicians. The company states that it optimises for impact over facetime and prefers collaboration to hierarchy. It was founded following its chief executive's wife's breast cancer diagnosis, and frames its work around the premise that the right data at the right time can change a patient's path.